Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SEL120-34A HCl 是一种可口服的,选择性的,ATP-竞争性的CDK8抑制剂,具有抗肿瘤活性,对 CDK8/CycC 和 CDK19/CycC 的IC50值分别为 4.4 nM 和 10.4 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 478 | 现货 | ||
5 mg | ¥ 1,160 | 现货 | ||
10 mg | ¥ 1,890 | 现货 | ||
25 mg | ¥ 3,230 | 现货 | ||
50 mg | ¥ 4,630 | 现货 | ||
100 mg | ¥ 6,490 | 现货 | ||
500 mg | ¥ 12,900 | 现货 |
产品描述 | SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), with antitumor activity. |
靶点活性 | CDK9/cycT:1070 nM (IC50), CDK19/CycC:10.4 nM (IC50), CDK8/CycC:4.4 nM (IC50) |
体外活性 | SEL120-34A HCl is a selective, ATP-competitive inhibitor of CDK8(IC50 of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively). SEL120-34A HCl is active against a panel of AML cell lines (GI50<1 μM), such as SKNO-1, KG-1, HEL-60, MOLM-16, MV-4-11, OciAML-2, MOLM-6 and OciAML-3 cells, consistent with the effective inhibition range of STAT1 S727 and STAT5 S726. |
体内活性 | The growth of tumor in mice bearing MV4-11 cancer cells inhibited by SEL120-34A (30, 60 mg/kg, p.o.), and also arrests the growth of KG-1-derived tumors at 30 mg/kg via oral administration. |
分子量 | 450.6 |
分子式 | C15H19Br2ClN4 |
CAS No. | 1609452-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL, sonification is recommended.
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SEL120-34A HCl 1609452-30-3 Cell Cycle/Checkpoint CDK SEL12034A HCl SEL-120-34A HCl Inhibitor SEL120 34A HCl Cyclin dependent kinase inhibit inhibitor